FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * SCHWARTZ BRIAN 2. Date of Event Requiring Statement (MM/DD/YYYY)
9/7/2021 

3. Issuer Name and Ticker or Trading Symbol INFINITY PHARMACEUTICALS, INC. [INFI]
(Last)       (First)       (Middle)
C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)
CAMBRIDGE, MA 02138      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 5/15/2030  Common Stock  60000  $0.99  D   
Stock Option (right to buy)   (2) 12/22/2030  Common Stock  56250  $2.14  D   

Explanation of Responses:
(1)  This option was granted on May 15, 2020. The option agreement provides that the option becomes exercisable in four equal semi-annual installments beginning on October 28, 2020. Pursuant to a resolution approved by the Issuer's Board of Directors on September 1, 2021, all remaining unvested options became exercisable effective as of September 6, 2021.
(2)  This option was granted on December 22, 2020. The option agreement provides that the option becomes exercisable in eight equal semi-annual installments beginning on June 22, 2021. Pursuant to a resolution approved by the Issuer's Board of Directors on September 1, 2021, 37,500 unvested options became exercisable effective as of September 6, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SCHWARTZ BRIAN
C/O INFINITY PHARMACEUTICALS, INC.
1100 MASSACHUSETTS AVENUE, FLOOR 4
CAMBRIDGE, MA 02138
X



Signatures
/s/ Brian Schwartz 9/9/2021
**Signature of Reporting Person Date
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Infinity Pharmaceuticals Charts.
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Infinity Pharmaceuticals Charts.